Clinical Trial Update: Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the impact of intensified raltegravir (MK-0518) on HIV-1 viral latency in patients who already had complete viral suppression.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• MK-0518 (raltegravir)
• Raltegravir (raltegravir)

Snippet

Sponsor: Germans Trias i Pujol Hospital | Conditions: HIV Infections | Phase 3 | Status: COMPLETED